Poway, CA (PRWEB) July 19, 2016 -- Robert Harman, DVM, Founder and CEO of Regenerative Veterinary Medicine Company VetStem Biopharma, Inc. is scheduled to speak at One Health Innovations – The Nexus of Human and Animal Medicine symposium in Kansas City, MO on Monday August 29th.
Dr Harman’s lecture, titled One Medicine- A Development Model for Cellular Therapy of Diabetes, will focus on how all mammals share similar stem cell biology and the clinical, experimental, manufacturing learning’s should be shared to expedite market approval in all species. Veterinary clinical data can be used as more realistic predictors of cell therapy outcomes in human clinical studies and reduce the cost and time to develop new therapies for dogs and humans.
He pulls from his biotechnology and veterinary experience to help VetStem perfect the clinical application of stem cell therapy for various types of injuries, illnesses, and other healing-promoting applications. VetStem is leading in the development for regenerative medicine in the veterinary field, with over 12,000 animals treated in the last 12 years.
The One Health Innovations- The Nexus of Human and Animal Medicine is presented as a partnership between the Schools of Veterinary Medicine at University of Missouri and Kansas State University, the Kansas City Area Life Sciences Institute. The two day symposium is focused on the translational and comparative aspects of human and animal medicine. The keynote speakers are Cheryl Stroud, DVM, PhD and Amy K. LeBlanc, DVM, DACVIM with a special guest speaker Luis Carlos Montalván. The symposium is designed for physicians, veterinarians, and scientists interested in research and clinical studies of cellular therapies.
VetStem first pioneered adipose derived stem cell therapy for use in horses for tendon injuries, as an alternative to euthanasia. Just two years after the first horse was treated, VetStem treated the first cat and dog. In 2007 the first peer reviewed, randomized, double-blinded, placebo controlled, multi-center study using VetStem therapy was published showing intra-articular injection of autologous adipose derived stem cells in the hip joint of a dog decreased patient discomfort and increased patient functional ability. That same year VetStem brought to market the Genesis Platelet Rich Plasma concentration system, as well as the first formal small animal stem cell credentialing course.
In 2015, VetStem (now VetStem Biopharma) announced the successful completion of a pilot efficacy study for allogeneic stem cell therapy (90 dogs, multi-center, blinded, placebo controlled) in support of an FDA INAD. Primary end point was statistically significant. The study has been submitted for peer reviewed publication. VetStem also entered into a distribution and clinical research agreement with Pall LifeSciences, including exclusive distribution rights in the US and Canada on V-PET™ platelet enhancement therapy system. V-PET™ is the only veterinary platelet therapy system supported by a JAVMA peer reviewed publication of a multi center, double-blinded, randomized study in dogs.
About VetStem Biopharma
VetStem Biopharma is a veterinarian-lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 14 years and 12,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.
Kristi Hauta, VetStem Biopharma, http://www.vet-stem.com/, +1 858-748-2004 Ext: 208, [email protected]
SOURCE VetStem Biopharma